In a symposium beginning at 4:15 p.m. ET, Hui Shao, MD, PhD, will discuss the financial implications on the health care system brought by these classes of agents, which have transformed diabetes care for individuals who also have cardiovascular disease.
Weighing the costs vs. benefits of SGLT2 inhibitors and GLP-1 receptor agonists
